The role of cell motility in prostate cancer

Cancer and Metastasis Reviews

Volumn 17, Issue 4, 1998, Pages 449-458

  Banyard, Jacqueline ^a   Zetter, Bruce R ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Invasion; Metastasis; Motility; Prostate cancer

Indexed keywords

ACTIN; CELL PROTEIN; CYTOKINE; GROWTH FACTOR RECEPTOR; PROTEINASE;

CANCER GROWTH; CANCER INHIBITION; CELL MOTILITY; CELL MOTION; DOWN REGULATION; GENE EXPRESSION; HORMONAL REGULATION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0032781527     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006150007710     Document Type: Review

References (72)

1. Gleason DF, Mellinger GT: Prediction of prognosis forprostate adenocarcinoma by combined histological gradingand clinical staging. J Urol 111: 58-64, 1974
2. Isaacs JT, Isaacs WB, Feitz WFJ, Scheres J: Establishmentand characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9:261-281, 1986
3. Dunning WP: Prostatic cancer in the rat. Natl Cancer InstitMonogr 12: 351-369, 1963
4. Mohler JL, Partin AW, Coffey DS: Prediction of metastaticpotential by a new grading system of cell motility: validationin the Dunning R-3327 prostatic adenocarcinoma model.J Urol 138: 168-170, 1987
5. Mohler JL, Partin AW, Isaacs JT, Coffey DS: Metastaticpotential predication by a visual grading system of cellmotility: prospective validation in the Dunning R-3327 prostatic adenocarcinoma model. Cancer Res 48: 4312-4317,1988
6. Partin AW, Schoeniger JS, Mohler JL, Coffey DS:Fourier analysis of cell motilily: correlation of motilitywith metastatic potential. Proc Natl Acad Sci USA 86:1254-1258, 1989
7. Doyle GM, Sharief Y, Mohler JL: Prediction of metastaticpotential by cancer cell motilily in the Dunning R-3327prostatic adenocarcinoma in vivo model. J Urol 147:514-518, 1992
8. Ching KZ, Ramsey E, Pettigrew N, D'Cunha R, Jason M,Doss JG: Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines. Mol Cell Biochem 126:151-158, 1993
9. Zolfaghari A, Djakiew D: Inhibition of chemomigration of ahuman prostatic carcinoma cell (TSU-Pr1) line by inhibitionof epidermal growth factor receptor function. Prostate 28:232-238, 1996
10. Xie H, Turner T, Wang M-H, Singh RK, Siegel GP, Wells A:In vitro invasiveness of DU-145 human prostate carcinomacells is modulated by EGF receptor-mediated signals. Clin Exp Metast 13: 407-419, 1995
11. Turner T, Chen P, Goodly LJ, Wells A: EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostatecarcinoma cells. Clin Exp Metast 4: 409-418, 1996
12. Hobeika AC, Etienne W, Cruz PE, Subramaniam PS, Johnson HM: IFNgamma induction of p21 WAFI in prostate cancer cells: role in cell cycle, alteration of phenotype andinvasive potential. Int J Cancer 77: 138-145, 1998
13. Evans CP, Walsh DS, Kohn EC: An autocrine motility factorsecreted by the Dunning R-3327 rat prostatic adenocarcinoma cell subtype AT2.1. Int J Cancer 49: 109-113, 1991
14. Silletti S, Yao JP, Pieta KJ, Raz A: Loss of cell-contact regulation and altered responses to autocrine motility factor correlate with increased malignancy in prostate cancer cells. Int J Cancer 63: 100-105, 1995
15. Morton DM, Barrack ER: Modulation of transforminggrowth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res 55: 2596-2602, 1995
16. Matuo Y, Nishi N, Takasuka H, Masuda Y, Nishikawa K,Isaacs JT, Adams PS, McKeehan WL, Sato GH: Productionand significance of TGF-beta in AT-3 metastatic cell lineestablished from the Dunning rat prostatic adenocarcinoma. Biochem Biophys Res Commun 166: 840-847, 1990
17. Guo Y, Jacobs SC, Kyprinou N: Down-regulation of proteinand mRNA expression for transforming growth factor-beta(TGF-beta 1) type I and type II receptors in human prostate cancer. Int J Cancer 71: 573-579, 1997
18. Ritchie CK, Andrews LR, Thomas KG, Tindall DJ, Fitzpatrick LA: The effects of growth factors associated withosteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. Endocrinology 138: 1145-1150, 1997
19. Figueroa JA, De Raad S, Tadlock L, Speights VO, Rinehart JJ: Differential expression of insulin-like growthfactor binding proteins in high versus low Gleason scoreprostate cancer. J Urol 159: 1379-1383, 1998
20. Aprikian AG, Tremblay L, Han K, Chevalier S: Bombesinstimulates the motility of human prostate-carcinoma cellsthrough tyrosine phosphorylation of focal adhesion kinaseand of integrin-associated proteins. Int J Cancer 72:498-504, 1997
21. Ritchie CK, Thomas KG, Andrews LR, Tindall DJ, Fitzpatrick LA: Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growthand chemotaxis. Prostate 30: 183-187, 1997
22. Wu G, Iwamura M, di Sant'Agnese PA, Deftos LJ, Cockett AT, Gersahgen S: Characterization of the cell-specific expression of parathyroid hormone-related proteinin normal and neoplastic prostate tissue. Urology (51; 5ASuppl): 110-120, 1998
23. Murphy BC, Pienta KJ, Coffey DS: Effects of extracellular matrix components and dihydrotestosterone on the structureand function of human prostate cancer cells. Prostate 20:29-41, 1992
24. Djakiew D, Pflug BR, Delsite R, Onoda M, Lynch JH,Arand G, Thompson EW: Chemotaxis and chemokinesisof human prostate tumor cell lines in response to humanprostate stromal cell secretory proteins containing a nervegrowth factor-like protein. Cancer Res 53: 1416-1420, 1993
25. Geldof AA, De Kleijn MA, Rao BR, Newling DW: Nervegrowth factor stimulates in vitro invasive capacity of DU145 human prostatic cancer cells. J Cancer Res Clin Oncol 123:107-112, 1997
26. Nishimura K, Kitamura M, Takeda S, Nonomura N, Tsujimura A, Matsumiya K, Miki T, Matsumoto K, Okuyama A: Regulation of invasive potential of humanprostate cancer cell lines by hepatocyte growth factor. Int J Urol 5: 276-281, 1998
27. Mohler JL, Bakewell WE, Sharief Y, Coleman WB, Chay CH, Silvers SM, Smith GJ: Detection of candidates for cancer cell motility inhibitory protein in the Dunning adenocarcinoma model. Clin Exp Metast 13: 474-480, 1995
28. Hullinger TG, McCauley LK, DeJoode ML, Somerman MJ:Effect of bone proteins on human prostate cancer cell linesin vitro. Prostate 36: 12-22, 1998
29. Freeman MR, Bagli DJ, Lamb CC, Guthrie PD, Uchida T, Slavin RE, Chung LW: Culture of a prostatic cell line in basement membrane gels results in an enhancement of malignantproperties and constitutive alterations in gene expression. J Cell Physiol 158: 325-336, 1994
30. Rabinovitz I, Nagle RB, Cress AE: Integrin alpha6 expression in human prostate carcinoma cells is associated with amigratory and invasive phenotype in vitro and in vivo. Clin Exp Metast 13: 481-491, 1995
31. Trikha M, Raso E, Cai Y, Fazakas Z, Paku S, Porter AT, Timar J, Honn KV: Role of alpha II (b)beta3 integrin in prostate cancer metastasis. Prostate 35: 185-192, 1998
32. Trikha M, Cai Y, Grignon D, Honn KV: Identificationof a novel truncated alpha 11b integrin. Cancer Res 58:4771-4775, 1998
33. Haywood-Reid PL, Zipf DR, Springer WR: Quantificationof integrin subunits on human prostatic cell lines: comparison of nontumorigenic and tumorigenic lines. Prostate 31:1-8, 1997
34. Gaylis FD, Keer HN, Wilson MJ, Kwaan HC, Sinha AA, Kozlowski JM: Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. J Urol 142: 193-198, 1989
35. Quax PH, de Bart AC, Schalken JA, Verheijen JH: Plasminogen activator and matrix metalloproteinase productionand extracellular matrix degradation by rat prostate cancercells in vitro: correlation with metastatic behavior in vivo. Prostate 32: 196-204, 1997
36. Lowe FC, Isaacs JT: Biochemical methods for predictingmetastatic ability of prostatic cancer utilizing the DunningR-3327 rat prostatic adenocarcinoma system as a model.Cancer Res 44: 744-52, 1984
37. Lokeshwar VB, Lokeshwar BL, Pham HT, Block NL: Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression. Cancer Res 56: 651-657, 1996
38. Sehgal G, Hua J, Bernhard EJ, Sehgal I, Thompson TC, Muschel RJ: Requirement for matrix metalloproteinase-9(gelatinase B) expression in metastasis by murine prostatecarcinoma. Am J Pathol 152: 591-596, 1998
39. Pienta KJ, Murphy BC, Isaacs WB, Isaacs JT, Coffey DS: Effect of Pentosan, a novel cancer chemotherapeutic agent,on prostate cancer cell growth and motility. Prostate 20:233-241, 1992
40. Mareel MM, Storme GA, Dragonetti CH, De Bruyne GK, Hartley-Asp B, Segers JL, Rabaey ML: Antiinvasive activityof estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro. Cancer Res 48:1842-1849, 1988
41. Kim JH, Tanabe T, Chodak GW, Rukstalis DB: In vitroanti-invasive effects of N-(4-hydroxyphenyl)-retinamideon human prostatic adenocarcinoma. Anticancer Res 15:1429-1434, 1995
42. Bao L, Loda M, Janmey PA, Stewart R, Anand-Apte B, Zetter BR: Thymosin β15: a novel regulator of tumor cellmotility upregulated in metastatic prostate cancer. Nature Med 2: 1322-1328, 1996
43. Keshgegian AA, Johnston E, Cnaan A: Bcl-2 oncoproteinpositivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol 110: 443-449, 1988
44. Del Bufalo D, Biroccio A, Leonetti C, Zupi G: Bcl-2 overexpression enhances the metastatic potential of a human breastcancer line. FASEB J 11: 947-953, 1997
45. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Pue J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH,Parsons R: PTEN, a putative protein tyrosine phosphatasegene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947, 1997
46. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada K: Inhibition of cell migration, spreading, and focaladhesions by tumor suppressor, PTEN. Science 280: 1614-1617, 1998
47. Tremblay L, Hauck W, Aprikian AG, Begin LR, Chapdelaine A, Chevalier S: Focal adhesion kinase(pp125FAK) expression, activation and association withpaxillin and p50CSK in human metastatic prostate carcinoma. Int J Cancer 68: 164-171, 1996
48. Zachary I: Focal adhesion kinase. Int J Biochem Cell Biol 29: 929-934, 1997
49. Dong J-T, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC: KAH, a metastasis suppressor gene for prostate cancer on human chromosome11p11.2. Science 268: 884-886, 1995
50. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr: p53, bcl-2 and retinoblastoma proteins as long term prognostic markers in localized carcinoma of the prostate. J Urol 158: 131-137, 1997
51. Li J, Hu SX, Perng GS, Zhou Y, Xu K, Zhang C, Seigne J, Benedict WF, Xu HJ: Expression of the retinoblastoma(RB) tumor suppressor gene inhibits tumor cell invasion invitro. Oncogene 13: 2379-2386, 1996
52. Kallakury BV, Yang F, Figge J, Smith KE, Kausik SJ, Tacy NJ, Fisher HA, Kaufman R, Figge H, Ross JS: Decreasedlevels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy. Cancer 78: 1461-1469, 1996
53. Gao AC, Lou W, Sleeman JP, Isaacs JT: Metastasis suppression by the standard CD44 isoform does not require thebinding of prostate cancer cells to hyaluronate. Cancer Res 58: 2350-2352, 1998
54. Miyake H, Hara I, Okamoto I, Gohji K, Yamanaka K, Arakawa S, Saya H, Kamidono S: Interaction between CD44and hyaluronic acid regulates human prostate cancer development. J Urol 160: 1562-1564, 1998
55. Bussemakers MJG, van Moorselaar RJA, Giroldi LA, Ichikawa T, Isaacs JT, Takeichi M, Debruyne FMJ, Schalken JA: Decreased expression of E-cadherin in the progressionof rat prostatic cancer. Cancer Res 52: 2916-2922, 1992
56. Kantor JD, McCormick B, Steeg PS, Zetter BR: Inhibition oftumor motility after nm23 transfection of human and murinetumor cells. Cancer Res 53: 1971-1973, 1993
57. Ray JM, Stetler-Stevenson WG: TIMP-2 expression modulates human melanoma cell adhesion and motility. Ann N Y Acad Sci. 732: 233-247, 1994
58. Takanaga K, Nakamura Y, Endo H, Sakiyama S: Involvement of S100-related calcium-binding protein pEL98 (ormts1) in cell motility and tumor cell invasion. Jpn J Cancer Res 85: 831-839, 1994
59. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530, 1995
60. Jarrard DF, Bova GS, Ewing CM, Pin SS, Nguyen SH, Baylin SB, Cairns P, Sidransky D, Herman JG, Isaacs WB: Deletional, mutational, and methylation analyses of CDKN2(p16/MTS1) in primary and metastatic prostate cancer. Gen Chrom Canc 19: 90-96, 1997
61. Gao X, Porter AT, Honn KV: Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in humanprostate cancer. Therapeutic implications. Av Exp Med Biol 417: 41-53, 1997
62. Sun Y, Lin J, Katz AE, Fisher PB: Human prostatic carcinoma oncogene PTI-1 is expressed in human tumor celllines and prostate carcinoma blood samples. Cancer Res 57:18-23, 1997
63. Rinker-Schaeffer CW, Chekmareva MA, Mohler JL: Therole of motility proteins and metastasis-suppressor genes in prostate cancer progression. Stem Cells 14: 508-516, 1996
64. Dong J-T, Isaacs WB, Isaacs JT: Molecular advances in prostate cancer. Curr Opin Oncology 9: 101-107, 1997
65. Fong CJ, Sutkowski DM, Kozlowski JM, Lee C: Utilizationof the Boyden chamber to further characterize in vitro migration and invasion of benign and malignant human prostaticepithelial cells. Invas Metast 12: 264-274, 1992
66. Wang FL, Wang Y, Ong WK, Liu Y, Addivinola FJ, Liang P, Chen LB, Kantoff PW, Pardee AB: Two differentially expressed genes in normal human prostate tissue and in carcinoma. Cancer Res 56: 3634-3637, 1996
67. Smith P, Rhodes NP, Shortland AP, Fraser SP, Djamgoz MB, Ke Y, Foster CS: Sodium channel protein expression enhances the invasiveness of rat and human prostate cancercells. FEBS Lett 423: 19-24, 1998
68. Viola MV, Fromowitz F, Oravez S, Deb S, Finkel G, Lundy J, Hand P, Thor A, Schlom J: Expression of ras oncogene p21 in prostate cancer. N Eng J Med 314: 133-137, 1986
69. Partin AW, Isaacs JT, Treiger B, Coffey DS: Early cell motility changes associated with an increase in metastatic abilityin rat prostatic cancer cells transfected with the v-Harvey-ras oncogene. Cancer Res 48: 6050-6053, 1988
70. Cooke DB, Quarmby VE, Petrusz P, Mickey DD, Der CJ, Isaacs JT, French FS: Expression of ras proto-oncogenes in the Dunning R3327 rat prostatic adenocarcinoma system. Prostate 13: 273-287, 1988
71. Powell CT, Gschwend JE, Fair WR, Brittis NJ, Stee D, Huryk R: Overexpression of protein kinase C-zeta (PKC-zeta) inhibits invasive and metastatic abilities of Dunning R-3327 MAT-LyLu rat prostate cancer cells. Cancer Res 56:4137-4141, 1996
72. Epner DE, Partin AW, Schalken JA, Isaacs JT, Coffey DS: Association of glyceraldehyde-3-phosphate dehydrogenase expression with cell motility and metastatic potential of ratprostatic adenocarcinoma. Cancer Res 53: 1995-1997, 1993